Measurement of Ki-67 antigen in 159 pituitary adenomas using the MIB-1 monoclonal antibody.
Pituitary adenomas sometimes show rapid growth and recurrence, and about one third invade the structures surrounding the sella turcica. In an attempt to determine aggressive behavior at an early stage, we used the MIB-1 antibody to identify the Ki-67 antigen. The present study was designed to evaluate pituitary adenomatous tissue in terms of secretion and proliferation and to correlate the Ki-67 index with hormone phenotype and invasive behavior. Material from 159 patients submitted to one or more resections of pituitary adenomas was evaluated. Forty-two non-secretory adenomas and 43 adenomas immunoreactive for growth hormone, 19 for prolactin, 18 for growth hormone and prolactin, 16 for adrenocorticotropic hormone (ACTH), and 21 cases of plurihormonal/gonadotropin adenomas were detected by immunohistochemistry. The MIB-1 antibody was positive in 139 samples and the Ki-67 index ranged from 0.16 to 15.48% (mean = 1.22 +/- 2.09%), with no significant difference between genders, age groups, or secretory and non-secretory status. The Ki-67 index was higher in ACTH-secreting adenomas. Invasive pituitary adenomas had a significantly higher Ki-67 index (2.01 +/- 3.15%) than macroadenomas with or without supra-sellar extension (1.12 +/- 1.87%; P = 0.02). The index was not significantly different in the subgroup of adenomas with invasion of the cavernous sinus compared to groups with other types of invasion. We conclude that tumoral proliferative activity evaluated by the detection of the Ki-67 antigen is significantly higher in invasive than noninvasive adenomas, information which can be useful in therapeutic postoperative management since index cut-off values associated with aggressive behavior can be established.
Pizarro
C B
CB
Departamento de Endocrinologia, Fundação Faculdade Federal de Ciências Médicas de Porto Alegre, Rua Dona Mimi Moro 40, 90480-050 Porto Alegre, RS, Brazil.
Oliveira
M C
MC
Coutinho
L B
LB
Ferreira
N P
NP
D000236:Adenoma / Q000276:immunology / Q000473:pathology*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000974:Antibodies, Antinuclear / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000276:immunology; D000951:Antigens, Neoplasm / Q000032:analysis*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000032:analysis*; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000276:immunology / Q000473:pathology; D010641:Phenotype; D010911:Pituitary Neoplasms / Q000276:immunology / Q000473:pathology*; D012658:Sella Turcica / Q000473:pathology
D000974:Antibodies, Antinuclear; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D019394:Ki-67 Antigen; C440408:MIB-1 antibody